



ÉCOLE POLYTECHNIQUE
FÉDÉRALE DE LAUSANNE

Faculty position in physics of quantum nanodevices

at the Swiss Federal Institute of Technology Lausanne (EPFL)

The Swiss Federal Institute of Technology in Lausanne (EPFL) is inviting applications for an assistant professor appointment (tenure-track) in its Institute of Quantum Electronics and Photonics.

The field of research should be well correlated with the topics pursued within the National Center of Competence in Research in Quantum Photonics (NCCR-QP) established with EPFL as the leading house, and involving a number of Swiss institutions. In particular, program orientations related to quantum devices incorporating low dimensionality semiconductors, more specifically III-V semiconductors, including nitrides, photonic bandgaps and microcavities will be considered favorably.

The appointee will have an interdisciplinary vision and a strong record of accomplishments and will initiate independent, creative research programs and participate in both undergraduate and graduate teaching. Substantial start-up resources will be available, in addition to the wide range of semiconductor epitaxial growth systems, characterization tools and processing facilities present in the Institute. Exceptional candidates could be hired as full professor.

We offer internationally competitive salaries and benefits.

Applications with curriculum vitae, publication list, concise statement of research and teaching interests as well as the names and addresses (including e-mail) of at least five references should be sent by **September 15, 2002**, to



Professor Giorgio Margaritondo
Dean
Faculty of Basic Sciences
EPFL
CH-1015 Lausanne, Switzerland

For additional information on the EPFL, please contact:
Prof. B. Deveaud-Plédran (deveaud@dpmail.epfl.ch)
and see the faculty web site :
<http://sb.epfl.ch/>, <http://ipeqwww.epfl.ch/>
or the NCCR web site <http://nccr-qp.epfl.ch>

The EPFL is an equal opportunity employer.

(SP92)



Medicines for Malaria Venture (MMV)



Funding Opportunities

CALL FOR LETTERS OF INTEREST

1. **Malaria Drug Discovery Research Proposals**
2. **Malaria Drug Development Proposals**
3. **Malaria Drug Natural Products R&D Proposals**

MMV is an independent foundation committed to the sustainable discovery and development of affordable antimalarial chemotherapies. It is based on a partnership between public sector agencies, philanthropic organisations and the pharmaceutical industry. The venture operates under the umbrella of the World Health Organization Roll Back Malaria Project.

MMV has currently a portfolio of 11 discovery and development projects that will be funded up to a level of \$15 million in 2002. MMV intends to expand its R&D portfolio in order to deliver a consistent stream of novel antimalarial agents over the next decade. Generous donations from several agencies now enable MMV to initiate a third round of portfolio projects for the year 2002. Three project categories are defined for this year's proposals.

1. **Malaria drug discovery projects** that are directed toward the identification of a candidate compound for entry into preclinical development.
 - Projects may be at an early or late stage of the discovery process.
 - Most successful projects in the previous years were based on a partnership between an academic centre and a pharmaceutical company. However, applications from single institutions (Academic or Biotech or Pharma) are welcome. The key determinant for funding will be the perceived chance of project success.
2. **Malaria drug development projects** where a single molecule or combination has been identified with demonstrably acceptable preclinical properties and a potential for clinical development.
 - The molecule (or combination) may be at either preclinical or clinical stage of development.
3. **Malaria Natural Product projects** are also solicited. They are more likely to succeed if applicants have a well-established infrastructure for a natural product programme, and can demonstrate one or more of the following characteristics:
 - Activity of the extracts, or identified compounds, against *P. falciparum* *in vitro* and in animal models, or evidence of efficacy in humans.
 - Methodology for the identification and optimisation of active agent(s). Projects that have already identified active agent(s) are strongly encouraged to apply.

Application for funding is initially requested through submission of a 3 page letter of interest, in hard copy, to reach MMV offices (see below) by September 30th, 2002.

Details of the desired content of the letter of interest for the three project categories, as well as the project selection process can be obtained from the MMV web site (www.mmv.org) or by directing inquiries to the MMV offices, to the attention of:

Dr. Solomon Nwaka, Medicines for Malaria Venture, MMV
International Center Cointrin, Entrance G, 3rd Floor, Route de Pre-Bois 20, P.O.Box 1826, CH-1215 Geneva 15, Switzerland
Fax +41 22 799 4061 E-mail: applications@mmv.org

MMV gratefully recognises the funding and support it has received from the following organisations: Bill and Melinda Gates Foundation, Global Forum for Health Research, International Federation of Pharmaceutical Manufacturers Associations, Rockefeller Foundation, Roll Back Malaria Partnership, Swiss Agency for Development and Cooperation, The Netherlands Minister for Development Cooperation, United Kingdom Department for International Development, World Bank, World Health Organization, ExxonMobil Foundation, WHO/TDR.

(SP94)